Table 4. The combined expression of USP14 and PSMD14 was correlated with clinicopathological features in NSCLC patients.

Characteristics	Combined expression of USP14 and PSMD14					P value
	1	2	3	4		Pa	Pb	Pc	Pd	Pe	Pf
Histological subtype						0.000*	0.362	0.001*	0.013*	0.457	0.049*
SCC	26	22	14	28
Adenocarcinoma	52	8	19	15
Age						0.769	0.044*	0.598	0.058	0.876	0.026*
≤50	31	11	20	15
>50	47	19	13	28
Gender						0.172	0.315	0.194	0.720	0.826	0.868
Male	49	23	24	32
Female	29	7	9	11
Smoking history						0.346	0.330	0.669	1.000	0.622	0.612
No	19	10	11	12
Yes	59	20	22	31
Tumor size (cm)						0.632	0.407	0.570	0.275	0.375	0.778
≤4	43	15	21	26
>4	35	15	12	17
Lymph node metastasis						0.002*	0.118	0.034*	0.154	0.240	0.731
No	37	24	21	29
Yes	41	6	12	14
TNM stage						0.003*	0.013*	0.005*	0.157	0.822	0.276
I	19	12	17	17
II	21	14	8	18
III + IV	38	4	8	8
Differentiation degree						0.214	0.248	0.164	0.319	0.694	0.082
Well	13	8	10	8
Moderate	40	17	13	28
Poor	25	5	10	7

1, high USP14 + high PSMD14; 2, high USP14 + low PSMD14; 3, low USP14 + low PSMD14; 4, low USP14 + high PSMD14; P^a, 1 vs. 2; P^b, 1 vs. 3; P^c, 1 vs. 4; P^d, 2 vs. 3; P^e, 2 vs. 4; P^f, 3 vs. 4. *, P<0.05. USP14, ubiquitin specific peptidase 14; PSMD14, proteasome 26S subunit, non-ATPase 14; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma.